Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous cyproterone acetate in previously untreated metastatic prostate cancer
NL-OMON21877Suspended
- Sponsor
- Erasmus MC
- Start
- Jan 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyproterone in prostate cancer (PCa), sponsored by Erasmus MC. Primary endpoint: Time to PSA progression after at least three months of continuous cyproterone acetate. Started Jan 2000; status: suspended.
02
Drugs
cyproterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON21877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21877.